M

Updated Results from the BLAST and TOWER Studies: Safety and Efficacy of Blinatumomab

By Michael Burke
0 views
April 20, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Recommended

AUTOPLAY
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
23:15
Rush University Medical Center

Is Post-HSCT Maintenance the SOC for AML?

Feat. M. Levis
16:28
Fred Hutchinson Cancer Center

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Feat. R. Cassaday
28:07
Indy Hematology Review

Controversies and Recommendations for the Treatment of ALL and Lymph…

Feat. W. Stock
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit
07:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…

Feat. L. Shune
11:35
Vanderbilt University Medical Center (VUMC)

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Feat. A. Jallouk
24:04
Indy Hematology Review

Treatment Strategies in MDS and ALL: Removing Bad Humor & Target…

Feat. R. Stone
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
04:11
Total Health

ASCO 2022 Updates in Leukemia and MDS

Feat. D. Sallman
11:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin
37:03
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: ALL

Feat. E. Jabbour
27:47
City of Hope

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

Feat. I. Amanam
03:36
Elias Jabbour

CRS and ICANS With BiTEs in ALL - How to Manage With Dose Adjustments

44:21
Tisch Cancer Institute at Mount Sinai

Early T-Cell Precursor ALL Case Discussion: Diagnosis, Prognosis, an…

Feat. A. Siegel
42:06
UNC Lineberger Comprehensive Cancer Center

Let’s Take a BiTE Out of CRS and Neurotoxicity

Feat. B. Kikani
04:45
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "The Impact of Inotuzumab Ozogamicin Treatme…

Feat. I. Aldoss
12:09
Pooja Khandelwal

Treating Fibrosis and Inflammation in GvHD